Rescue of gene expression by modified REST decoy oligonucleotides in a cellular model of Huntington's disease

Journal of Neurochemistry

Volumn 116, Issue 3, 2011, Pages 415-425

  Soldati, Chiara ^a   Bithell, Angela ^a   Conforti, Paola ^b   Cattaneo, Elena ^b   Buckley, Noel J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

brain derived neurotrophic factor; decoy oligonucleotides; histone modification; Huntington's disease; repressor element 1 silencing transcription factor; transcriptional dysregulation

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HUNTINGTIN; OLIGONUCLEOTIDE; REPRESSOR ELEMENT 1 SILENCING TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MOUSE; MUTANT; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PRIORITY JOURNAL; REPRESSOR GENE; TRANSCRIPTION REGULATION;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL LINE; GENE EXPRESSION REGULATION; GENE KNOCK-IN TECHNIQUES; GENE SILENCING; GENE THERAPY; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDES; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 78651318398     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.07122.x     Document Type: Article

References (84)

1. Abrajano J. J., Qureshi I. A., Gokhan S., Zheng D., Bergman A., and, Mehler M. F., (2009a) Differential deployment of REST and CoREST promotes glial subtype specification and oligodendrocyte lineage maturation. PLoS ONE 4, e7665.
2. Abrajano J. J., Qureshi I. A., Gokhan S., Zheng D., Bergman A., and, Mehler M. F., (2009b) REST and CoREST modulate neuronal subtype specification, maturation and maintenance. PLoS ONE 4, e7936.
3. Aharoni-Simon M., Reifen R., and, Tirosh O., (2006) ROS-production- mediated activation of AP-1 but not NFkappaB inhibits glutamate-induced HT4 neuronal cell death. Antioxid. Redox Signal. 8, 1339-1349.
4. Altar C. A., Cai N., Bliven T., Juhasz M., Conner J. M., Acheson A. L., Lindsay R. M., and, Wiegand S. J., (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389, 856-860.
5. Bae B. I., Xu H., and, Igarashi S., et al. (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29-41.
6. Ballas N., Battaglioli E., and, Atouf F., et al. (2001) Regulation of neuronal traits by a novel transcriptional complex. Neuron 31, 353-365.
7. Bates G. P., (2005) History of genetic disease: the molecular genetics of Huntington disease-a history. Nat. Rev. Genet. 6, 766-773.
8. Battaglioli E., Andres M. E., Rose D. W., Chenoweth J. G., Rosenfeld M. G., Anderson M. E., and, Mandel G,. (2002) REST repression of neuronal genes requires components of the hSWI.SNF complex. J. Biol. Chem. 277, 41038-41045.
9. Bithell A., Johnson R., and, Buckley N. J., (2009) Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease. Biochem. Soc. Trans. 37, 1270-1275.
10. Brown D. A., Kang S. H., Gryaznov S. M., DeDionisio L., Heidenreich O., Sullivan S., Xu X., and, Nerenberg M. I., (1994) Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801-26805.
11. Bruce A. W., Donaldson I. J., Wood I. C., Yerbury S. A., Sadowski M. I., Chapman M., Gottgens B., and, Buckley N. J., (2004) Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. Proc. Natl Acad. Sci. USA 101, 10458-10463.
12. Buckley N. J., Johnson R., Zuccato C., Bithell A., and, Cattaneo E., (2010) The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol. Dis. 39, 28-39.
13. Calderone A., Jover T., and, Noh K. M., et al. (2003) Ischemic insults derepress the gene silencer REST in neurons destined to die. J. Neurosci. 23, 2112-2121.
14. Canals J. M., Pineda J. R., Torres-Peraza J. F., Bosch M., Martin-Ibanez R., Munoz M. T., Mengod G., Ernfors P., and, Alberch J., (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24, 7727-7739.
15. Cattaneo E., Zuccato C., and, Tartari M., (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919-930.
16. Chae Y. M., Park K. K., Lee I. K., Kim J. K., Kim C. H., and, Chang Y. C., (2006) Ring-Sp1 decoy oligonucleotide effectively suppresses extracellular matrix gene expression and fibrosis of rat kidney induced by unilateral ureteral obstruction. Gene Ther. 13, 430-439.
17. Chong J. A., Tapia-Ramirez J., and, Kim S., et al. (1995) REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 80, 949-957.
18. Copeland R. A., Olhava E. J., and, Scott M. P., (2010) Targeting epigenetic enzymes for drug discovery. Curr. Opin. Chem. Biol. 14, 505-510.
19. Crinelli R., Bianchi M., Gentilini L., and, Magnani M., (2002) Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res. 30, 2435-2443.
20. Dash P. K., Orsi S. A., and, Moore A. N., (2005) Sequestration of serum response factor in the hippocampus impairs long-term spatial memory. J. Neurochem. 93, 269-278.
21. De Stefano D., De Rosa G., and, Carnuccio R., (2010) NFkappaB decoy oligonucleotides. Curr. Opin. Mol. Ther. 12, 203-213.
22. Dhalluin C., Carlson J. E., Zeng L., He C., Aggarwal A. K., and, Zhou M. M., (1999) Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491-496.
23. Dunah A. W., Jeong H., and, Griffin A., et al. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238-2243.
24. Ferrante R. J., Kubilus J. K., and, Lee J., et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418-9427.
25. Gao W. Y., Han F. S., Storm C., Egan W., and, Cheng Y. C., (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol. 41, 223-229.
26. Garriga-Canut M., Schoenike B., and, Qazi R., et al. (2006) 2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat. Neurosci. 9, 1382-1387.
27. Greenway D. J., Street M., Jeffries A., and, Buckley N. J., (2007) RE1 Silencing transcription factor maintains a repressive chromatin environment in embryonic hippocampal neural stem cells. Stem Cells 25, 354-363.
28. Griesenbach U., Cassady R. L., Cain R. J., duBois R. M., Geddes D. M., and, Alton E. W., (2002) Cytoplasmic deposition of NFkappaB decoy oligonucleotides is insufficient to inhibit bleomycin-induced pulmonary inflammation. Gene Ther. 9, 1109-1115.
29. Grimes J. A., Nielsen S. J., and, Battaglioli E., et al. (2000) The co-repressor mSin3A is a functional component of the REST-CoREST repressor complex. J. Biol. Chem. 275, 9461-9467.
30. Hake S. B., Xiao A., and, Allis C. D., (2004) Linking the epigenetic 'language' of covalent histone modifications to cancer. Br. J. Cancer 90, 761-769.
31. Hakimi M. A., Bochar D. A., Chenoweth J., Lane W. S., Mandel G., and, Shiekhattar R., (2002) A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc. Natl Acad. Sci. USA 99, 7420-7425.
32. Hara T., Hamada J., Yano S., Morioka M., Kai Y., and, Ushio Y., (2003) CREB is required for acquisition of ischemic tolerance in gerbil hippocampal CA1 region. J. Neurochem. 86, 805-814.
33. Hara D., Fukuchi M., Miyashita T., Tabuchi A., Takasaki I., Naruse Y., Mori N., Kondo T., and, Tsuda M., (2009) Remote control of activity-dependent BDNF gene promoter-I transcription mediated by REST/NRSF. Biochem. Biophys. Res. Commun. 384, 506-511.
34. Huang C. C., Faber P. W., Persichetti F., Mittal V., Vonsattel J. P., MacDonald M. E., and, Gusella J. F., (1998) Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 24, 217-233.
35. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72, 971-983.
36. Jenuwein T., and, Allis C. D., (2001) Translating the histone code. Science 293, 1074-1080.
37. Johnson R., and, Buckley N. J., (2009) Gene Dysregulation in Huntington's Disease: REST, MicroRNAs and Beyond. Neuromol. Med. 11, 183-199.
38. Johnson R., Gamblin R. J., Ooi L., Bruce A. W., Donaldson I. J., Westhead D. R., Wood I. C., Jackson R. M., and, Buckley N. J., (2006) Identification of the REST regulon reveals extensive transposable element-mediated binding site duplication. Nucleic Acids Res. 34, 3862-3877.
39. Johnson D. S., Mortazavi A., Myers R. M., and, Wold B., (2007) Genome-wide mapping of in vivo protein-DNA interactions. Science 316, 1497-1502.
40. Johnson R., Teh C. H., and, Kunarso G., et al. (2008a) REST regulates distinct transcriptional networks in embryonic and neural stem cells. PLoS Biol. 6, e256.
41. Johnson R., Zuccato C., Belyaev N. D., Guest D. J., Cattaneo E., and, Buckley N. J., (2008b) A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol. Dis. 29, 438-445.
42. Kazantsev A. G., and, Hersch S. M., (2007) Drug targeting of dysregulated transcription in Huntington's disease. Prog. Neurobiol. 83, 249-259.
43. Kazantsev A. G., and, Thompson L. M., (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7, 854-868.
44. Kim M. O., Chawla P., Overland R. P., Xia E., Sadri-Vakili G., and, Cha J. H., (2008) Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation. J. Neurosci. 28, 3947-3957.
45. Kraner S. D., Chong J. A., Tsay H. J., and, Mandel G., (1992) Silencing the type II sodium channel gene: a model for neural-specific gene regulation. Neuron 9, 37-44.
46. Kubo T., Kinjyo N., Ikezawa A., Kambe T., and, Fukumori R., (2003) Sp1 decoy oligodeoxynucleotide decreases angiotensin receptor expression and blood pressure in spontaneously hypertensive rats. Brain Res. 992, 1-8.
47. Kuwabara T., Hsieh J., Nakashima K., Taira K., and, Gage F. H., (2004) A small modulatory dsRNA specifies the fate of adult neural stem cells. Cell 116, 779-793.
48. Lee I. K., Ahn J. D., Kim H. S., Park J. Y., and, Lee K. U., (2003) Advantages of the circular dumbbell decoy in gene therapy and studies of gene regulation. Curr. Drug Targets 4, 619-623.
49. Lee M. G., Wynder C., Cooch N., and, Shiekhattar R., (2005) An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437, 432-435.
50. Marullo M., Valenza M., Mariotti C., Di Donato S., Cattaneo E., and, Zuccato C., (2008) Analysis of the Repressor Element-1 Silencing Transcription Factor/Neuron-Restrictive Silencer Factor Occupancy of Non-Neuronal Genes in Peripheral Lymphocytes from Patients with Huntington's Disease. Brain Pathol. 20, 96-105.
51. Meller R., Minami M., Cameron J. A., Impey S., Chen D., Lan J. Q., Henshall D. C., and, Simon R. P., (2005) CREB-mediated Bcl-2 protein expression after ischemic preconditioning. J. Cereb. Blood Flow Metab. 25, 234-246.
52. Mori N., Schoenherr C., Vandenbergh D. J., and, Anderson D. J., (1992) A common silencer element in the SCG10 and type II Na+ channel genes binds a factor present in nonneuronal cells but not in neuronal cells. Neuron 9, 45-54.
53. Nucifora Jr. F. C., Sasaki M., and, Peters M. F., et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423-2428.
54. Ooi L., and, Wood I. C., (2007) Chromatin crosstalk in development and disease: lessons from REST. Nat. Rev. Genet. 8, 544-554.
55. Ooi L., Belyaev N. D., Miyake K., Wood I. C., and, Buckley N. J., (2006) BRG1 chromatin remodeling activity is required for efficient chromatin binding by repressor element 1-silencing transcription factor (REST) and facilitates REST-mediated repression. J. Biol. Chem. 281, 38974-38980.
56. Osako M. K., Tomita N., and, Nakagami H., et al. (2007) Increase in nuclease resistance and incorporation of NF-kappaB decoy oligodeoxynucleotides by modification of the 3′-terminus. J. Gene Med. 9, 812-819.
57. Palm K., Belluardo N., Metsis M., and, Timmusk T., (1998) Neuronal expression of zinc finger transcription factor REST/NRSF/XBR gene. J. Neurosci. 18, 1280-1296.
58. Pfaffl M. W., Georgieva T. M., Georgiev I. P., Ontsouka E., Hageleit M., and, Blum J. W., (2002) Real-time RT-PCR quantification of insulin-like growth factor (IGF)-1, IGF-1 receptor, IGF-2, IGF-2 receptor, insulin receptor, growth hormone receptor, IGF-binding proteins 1, 2 and 3 in the bovine species. Domest. Anim. Endocrinol. 22, 91-102.
59. Roopra A., Sharling L., Wood I. C., Briggs T., Bachfischer U., Paquette A. J., and, Buckley N. J., (2000) Transcriptional repression by neuron-restrictive silencer factor is mediated via the Sin3-histone deacetylase complex. Mol. Cell. Biol. 20, 2147-2157.
60. Roopra A., Qazi R., Schoenike B., Daley T. J., and, Morrison J. F., (2004) Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes. Mol. Cell 14, 727-738.
61. Rubinsztein D. C., and, Carmichael J., (2003) Huntington's disease: molecular basis of neurodegeneration. Expert Rev. Mol. Med. 5, 1-21.
62. Ryu H., Lee J., Hagerty S. W., Soh B. Y., McAlpin S. E., Cormier K. A., Smith K. M., and, Ferrante R. J., (2006) ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl Acad. Sci. USA 103, 19176-19181.
63. Sadri-Vakili G., Bouzou B., and, Benn C. L., et al. (2007) Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 16, 1293-1306.
64. Schoenherr C. J., and, Anderson D. J., (1995) The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science 267, 1360-1363.
65. Schoenherr C. J., Paquette A. J., and, Anderson D. J., (1996) Identification of potential target genes for the neuron-restrictive silencer factor. Proc. Natl Acad. Sci. USA 93, 9881-9886.
66. Shogren-Knaak M., Ishii H., Sun J. M., Pazin M. J., Davie J. R., and, Peterson C. L., (2006) Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311, 844-847.
67. Spencer E. M., Chandler K. E., and, Haddley K., et al. (2006) Regulation and role of REST and REST4 variants in modulation of gene expression in in vivo and in vitro in epilepsy models. Neurobiol. Dis. 24, 41-52.
68. Stadlbauer T. H., Wagner A. H., Holschermann H., Fiedel S., Fingerhuth H., Tillmanns H., Bohle R. M., and, Hecker M., (2008) AP-1 and STAT-1 decoy oligodeoxynucleotides attenuate transplant vasculopathy in rat cardiac allografts. Cardiovasc. Res. 79, 698-705.
69. Steffan J. S., Kazantsev A., and, Spasic-Boskovic O., et al. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 97, 6763-6768.
70. Steiger J. L., Bandyopadhyay S., Farb D. H., and, Russek S. J., (2004) cAMP response element-binding protein, activating transcription factor-4, and upstream stimulatory factor differentially control hippocampal GABABR1a and GABABR1b subunit gene expression through alternative promoters. J. Neurosci. 24, 6115-6126.
71. Sun Y. M., Greenway D. J., Johnson R., Street M., Belyaev N. D., Deuchars J., Bee T., Wilde S., and, Buckley N. J., (2005) Distinct Profiles of REST Interactions with Its Target Genes at Different Stages of Neuronal Development. Mol. Biol. Cell 16, 5630-5638.
72. Thomas E. A., Coppola G., and, Desplats P. A., et al. (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl Acad. Sci. USA 105, 15564-15569.
73. Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V. C., Sharp A. H., Persichetti F., Cattaneo E., and, MacDonald M. E., (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 2799-2809.
74. Yang Y., Tesmer V. M., and, Bina M., (2002) Regulation of HIV-1 transcription in activated monocyte macrophages. Virology 299, 256-265. (Pubitemid 35356602)
75. Yao Y., Kubota T., Sato K., Takeuchi H., Kitai R., and, Matsukawa S., (2005) Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells. J. Neurooncol. 72, 217-223.
76. Ye S. M., and, Johnson R. W., (2001) Regulation of interleukin-6 gene expression in brain of aged mice by nuclear factor kappaB. J. Neuroimmunol. 117, 87-96.
77. Zala D., Benchoua A., Brouillet E., Perrin V., Gaillard M. C., Zurn A. D., Aebischer P., and, Deglon N., (2005) Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol. Dis. 20, 785-798.
78. Zuccato C., and, Cattaneo E., (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 81, 294-330.
79. Zuccato C., and, Cattaneo E., (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5, 311-322.
80. Zuccato C., Ciammola A., and, Rigamonti D., et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498.
81. Zuccato C., Tartari M., and, Crotti A., et al. (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35, 76-83.
82. Zuccato C., Belyaev N., and, Conforti P., et al. (2007) Widespread disruption of repressor element-1 silencing transcription factor/neuron- restrictive silencer factor occupancy at its target genes in Huntington's disease. J. Neurosci. 27, 6972-6983.
83. Zuccato C., Marullo M., Conforti P., MacDonald M. E., Tartari M., and, Cattaneo E., (2008) Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 18, 225-238.
84. Zuccato C., Valenza M., and, Cattaneo E., (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 90, 905-981.